Edition:
India

Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

6.80USD
2:29am IST
Change (% chg)

$0.30 (+4.62%)
Prev Close
$6.50
Open
$6.55
Day's High
$6.80
Day's Low
$6.55
Volume
36,697
Avg. Vol
18,794
52-wk High
$6.80
52-wk Low
$3.35

Summary

Name Age Since Current Position

Al Kraus

70 2008 Chairman of the Board

Phillip Chan

45 2009 President, Chief Executive Officer, Director

Kathleen Bloch

58 2013 Chief Financial Officer

Vincent Capponi

55 2005 Chief Operating Officer

Eric Mortensen

2017 Chief Medical Officer

Michael Bator

2015 Director

James Gunton

49 2008 Independent Director

Edward Jones

66 2007 Independent Director

Alan Sobel

54 2014 Independent Director

Biographies

Name Description

Al Kraus

Mr. Al Kraus is Chairman of the Board of CytoSorbents Corporation effective December 2008. Mr. Kraus has been a director of the Company since 2003 and up until the end of 2008 was the Company’s President and CEO. Mr. Kraus currently serves as Chairman of the Board of Directors. Mr. Kraus has more than twenty-five years’ experience managing companies in the dialysis, medical device products, personal computer and custom software industries. Prior to joining the compeny, from 2001 to 2003, Mr. Kraus was President and CEO of NovoVascular Inc., an early stage company developing coated stent technology. From 1996 to 1998, Mr. Kraus was President and CEO of Althin Healthcare and from 1998 to 2000, of Althin Medical Inc., a manufacturer of products for the treatment of end stage renal disease. While CEO of Althin, he provided strategic direction and management for operations throughout the Americas. From 1979 to 1985, Mr. Kraus was U.S. Subsidiary Manager and Chief Operating Officer of Gambro Inc., a medical technology and healthcare company. Mr. Kraus was the Chief Operating Officer of Gambro when it went public in the United States in an offering led by Morgan Stanley.

Phillip Chan

Dr. Phillip P. Chan, M.D., Ph.D., is President, Chief Executive Officer and Director of CytoSorbents Corp. Dr. Chan became a director of the Company in 2008 and since January 2009 is also Chief Executive Officer. Prior to CytoSorbents, Dr. Chan led healthcare and life science investments as Partner for the NJTC Venture Fund. Dr. Chan co-founded Andrew Technologies, a medical device company developing novel surgical instruments for plastic surgery. He is a Board-certified Internal Medicine physician with a background in clinical medicine and research. Dr. Chan received his MD and PhD from the Yale University School of Medicine and completed his Internal Medicine residency at Beth Israel Deaconess Medical Center at Harvard. He also holds a BS in cell and molecular biology from Cornell University.

Kathleen Bloch

Ms. Kathleen P. Bloch, MBA, CPA, has been appointed as Chief Financial Officer of CytoSorbents Corporation effective May 29, 2013. Ms. Bloch has more than 20 years of executive financial experience in both public and private companies. Most recently, she was Chief Financial Officer of Laureate Biopharmaceutical Services, Inc. Previously, Ms. Bloch was Chief Operating Officer and CFO of PC Group, Inc., a $70 million in revenue, NASDAQ-listed, publicly traded company with a diverse group of holdings, including several medical device subsidiaries. Prior to that, Ms. Bloch was CFO of Silver Line Building Products Corporation for seven years, helping it grow from $100 million in sales, into the manufacturer of vinyl windows with more than $750 million in revenue, employing over 7,000 people nationwide in 35 states with nine manufacturing facilities. In 2006, she oversaw the acquisition of Silver Line by Andersen Corporation, an international manufacturer of windows. Previously, Ms. Bloch was CFO of ERD Waste Corporation, a NASDAQ-listed, publicly-traded environmental services provider, operating in 16 states with more than $60 million in sales. She began her career at Peat Marwick International, which became KPMG LLP, one of the big four accounting firms. Ms. Bloch holds a Master of Business Administration degree and a Bachelor of Science Accounting degree from LaSalle University, and is a Certified Public Accountant.

Vincent Capponi

Mr. Vincent J. Capponi is Chief Operating Officer of CytoSorbents Corp. Mr. Capponi joined the Company as Vice President of Operations in 2002 and became its Chief Operating Officer in July 2005. He has more than 20 years of management experience in medical device, pharmaceutical and imaging equipment at companies including Upjohn, Sims Deltec and Sabratek. Prior to joining CytoSorbents in 2002, Mr. Capponi held several senior management positions at Sabratek and its diagnostics division GDS, and was interim president of GDS diagnostics in 2001. From 1998 to 2000, Mr. Capponi was Senior Vice President and Chief Operating Officer for Sabratek and Vice President Operations from 1996 to 1998. He received his MS in Chemistry and his BS in Chemistry and Microbiology from Bowling Green State University.

Eric Mortensen

Dr. Eric G. Mortensen is the Chief Medical Officer of the Company. Dr. Mortensen received an A.B. in Biochemistry fromHarvard College, an M.D. from theHarvard Universityand Massachusetts Institute of Technology Division of Health Sciences and Technology (HST), and a Ph.D. in Biophysics at theHarvard Graduate School of Arts and Scienceswhere he studied the transduction of membrane-bound hormone receptor's binding into intracellular activation of metabolic activity and cellular proliferation. Dr. Mortensen completed an internship and residency in Internal Medicine at the Massachusetts General Hospital and a fellowship in Gastroenterology at theUniversity of MichiganMedical Center,Ann Arbor.

Michael Bator

Mr. Michael G. Bator is Director of CytoSorbents Corporation. Mr. Bator was most recently a Managing Director of Healthcare Research at Jennison Associates, a U.S. mutual and pension fund management company that currently manages $188 billion in assets. During his 14 years at Jennison, Mr. Bator evaluated and recommended a wide array of investments in medical devices, European pharmaceuticals, managed care companies, and many others including well-known companies such as Medtronic, Abbott , Baxter, Johnson and Johnson, Novartis, AstraZeneca, Roche and GSK. Mr. Bator also has extensive management consulting experience, having spent many years with Cambridge Pharma Consultancy, Lexington Strategy, and The Boston Consulting Group. Mr. Bator received his MBA in Finance from Wharton Business School at the University of Pennsylvania , and his BA from Princeton University . He will serve on the executive compensation committee of the CytoSorbents Board.

James Gunton

Mr. James T. Gunton, MBA., is an Independent Director of CytoSorbents Corporation., since 2008. Since 2001, Mr. Gunton has served as general partner of NJTC Venture Fund, L.P. Mr. Gunton has been investing in privately held and publicly traded growth technology and services companies for twenty years. Before co-founding NJTC Venture Fund in 2001, Mr. Gunton was a partner at Edison Venture Fund from 1994 to 2000 and a rapidly-promoted manager at Oracle Corporation in the Silicon Valley from 1988 to 1991. Mr. Gunton has generated several billion dollars of market value through involvement with more than 30 private and public emerging growth companies.

Edward Jones

Dr. Edward R. Jones, M.D., MBA, is an Independent Director of CytoSorbents Corporation., since April 2007. Dr. Jones is an attending physician at the Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital. Dr. Jones has published or contributed to the publishing of 30 chapters, articles, and abstracts on the subject of treating kidney-related illnesses. He is a sixteen-year member of the Renal Physicians Association, the Philadelphia County Medical Society and a past board member of the National Kidney Foundation of the Delaware Valley. From March 2009 to March 2011, Dr. Jones was President of, and currently serves as a Counselor at, the Renal Physicians Association. Since January, 2014, Dr. Jones is Chairman of Kidney Care Partners and he is the President and Managing Director of his nephrology practice (Delaware Valley Nephrology and Hypertension, Associates).

Alan Sobel

Alan D. Sobel is an Independent Director of CytoSorbents Corporation since November 2014. Since 1996, Mr. Sobel has served as the Managing Member of Sobel & Co., LLC, a full-service accounting, auditing, taxation, and business consulting firm. He has provided corporate advisory and consulting services, including mergers and acquisitions, for clients in the real estate, manufacturing, pharmaceutical, and distribution businesses, among others. Mr. Sobel is a Certified Public Accountant, and has served in various leadership roles including Chairman of the Audit Committee of the New Jersey Society of Certified Public Accountants.

Basic Compensation

Name Fiscal Year Total

Al Kraus

324,732

Phillip Chan

318,261

Kathleen Bloch

270,000

Vincent Capponi

301,945

Eric Mortensen

--

Michael Bator

--

James Gunton

--

Edward Jones

--

Alan Sobel

--
As Of  31 Dec 2014